Lyell Immunopharma, Inc. (LYEL) is in Healthcare, Biotechnology, based in United States, listed on NasdaqGS. Market cap 215.40M USD. 52-week range 8.21 to 45.00 USD. Data as of 2026-10-09.
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company's lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial, PiNACLE-H2H, which ...